Celgene Corp. coasted through currency exchange headwinds. Vertex Pharmaceuticals Inc. focused on its emerging pipeline after soft Orkambi sales. And Gilead Sciences Inc. fell shy of analyst expectations. Amgen Inc. saved the day with higher-than-expected profits and raised guidance.